Navigation Links
Avipaxin Is First Entrant in Medical Arsenal for Neuro-Endocrine-Immune Connection(C) Product and Testing Protocols
Date:8/4/2009

OSCEOLA, Wis., Aug. 4 /PRNewswire/ -- NeuroScience, Inc. has launched a new product -- Avipaxin -- aimed at decreasing elevated levels of pro-inflammatory cytokines. Avipaxin supports acetylcholine levels by providing substrates for its production and by inhibiting its metabolizing enzyme, acetylcholinesterase. Initial studies at NeuroScience, Inc. revealed a significant decrease in pro-inflammatory cytokines and chemokines after Avipaxin use. These studies also revealed a decrease in the neurotransmitter norepinephrine and an increase in the neurotransmitter serotonin.

Historically, neurotransmitters, cytokines, and hormones were considered signal messengers of the Nervous, Endocrine, and Immune systems, respectively. However, recent evidence shows that those systems are actually part of a single and integrated Neuro-Endocrine-Immune (NEI) Connection(C).

Elevated pro-inflammatory cytokine levels lead to imbalances in neurotransmitter concentrations and raised hormone (cortisol) levels. Neurotransmitters are responsible for people's mood, concentration, sleep, and other mental and emotional functions. Cytokine-induced neurotransmitter imbalances are regularly noticed when people are sad, lethargic, and are unable to focus during an acute viral or bacterial infection. Serotonin, which was increased in the Avipaxin studies, is a particularly important neurotransmitter involved with mood and sleep. Research shows that persistent cytokine elevations lead to numerous physical and emotional symptoms that are difficult to manage.

Avipaxin modulates elevated cytokine levels by supporting acetylcholine-mediated signaling. The cholinergic anti-inflammatory pathway uses the neurotransmitter acetylcholine to down-regulate elevated pro-inflammatory cytokines. Decreasing pro-inflammatory cytokines leads to an indirect normalization of neurotransmitter levels, leading to a positive effect on mood, concentration, sleep, and other emotional and mental processes. Avipaxin should be considered for patients with suspected acute or persistent immune system activation.

Additional information regarding Avipaxin can be found at www.neurorelief.com/avipaxin.

About NeuroScience, Inc.:

NeuroScience, Inc, established in 1999, is devoted to medical solutions that improve health by providing novel laboratory assessments and products in the emerging field of NeuroEndocrine Immunology (NEI). The company is research and education-focused and has a database that includes results from over 300,000 patients.


'/>"/>
SOURCE NeuroScience, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. First biomarker discovered that predicts prostate cancer outcome
2. FDA Approves First Anti-Psychotic for Kids
3. Single-incision belly-button surgery to remove kidney performed first at UT Southwestern
4. First study examines newly-licensed RN work attitudes and intentions
5. Glades General Hospital First in Palm Beach County to Provide On-Site Electronic Birth Registration
6. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
7. Father and Daughter From Tanzania Receive Their First Medical Examination in Newport Beach
8. High and mighty: first common height gene identified by researchers behind obesity gene finding
9. APA Comments on FDAs First Approval of Medication to Treat Pediatric Schizophrenia and Bipolar Disorder
10. TriWest Creates First-of-its-Kind Partnership to Offer Military Leaders With Grief Support Program
11. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief ... a minimum wage raise to $12 an hour by 2020 and then adjusting it yearly ... lost value of the minimum wage, assure the wage floor does not erode again, and ...
(Date:6/24/2016)... Georgia (PRWEB) , ... June 24, 2016 , ... ... awards today at the Clinical Decision Making in Emergency Medicine conference in Ponte ... have authored journal articles published in Emergency Medicine Practice and Pediatric ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Investment Group (TGIG), has initiated cultivation and processing operations at its production facility, ... Pahrump, Nevada. , Puradigm is the manufacturer of a complete system of proactive ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone Partners ... extensive sequencing and genomics experience, as Vice President of North American Capital Sales at ... responsible for leading the sales team in the commercialization of the HTG EdgeSeq system ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... human induced pluripotent stem (iPS) cells and other difficult to transfect cells, announces ... Medium. The PluriQ™ G9™ Gene Editing System is a complete system ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... 2022" report to their offering. ... with kidney failure, it replaces the function of kidneys by ... and thus the treatment helps to keep the patient body,s ... Increasing number of ESRD patients & substantial healthcare ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
Breaking Medicine Technology: